Non-Compliant Balloons Improve Bifurcation Outcomes

Courtesy of Dr. Carlos Fava.

non compliant balloonsThe provisional approach is the standard strategy to treat bifurcations, but it might cause dissection of the ostium, a serious complication of the side branch. The use of non-compliant balloons (NCB) ensures uniform, constant, and controlled expansion along balloon length, reducing the risk of dissection.

The COBIS II registry enrolled 2,897 patients with bifurcation lesions (≥2.5 mm main vessel and ≥2.3 mm side branch diameters).

26% (752 patients) were treated with NCB. After propensity score matching, there were 710 patients in each group.

Procedural success was higher in patients receiving NCB:

 

With NCB: 79%

Without NCB: 73.9%

[p=0.01]

 

Angiographic success of side branch was:

 

With NCB: 79.7 %

Without NCB: 75.4%

[p=0.03].

 

The use of NCB positively correlated with lower SB dissection (0.1% vs. 1.1%; p=0.04)

Follow up was at 36 months in 96.3% of the population. Combined events rate resulted lower in the NCB group (HR 0.64, CI 95% 0.46-0.91; p=0.01), same as cardiac death (HR 0.14, CI 95% 0.03-0. 64; p=0.01) and stent thrombosis (probable, definite and possible) and there was a tendency towards a lower target vessel revascularization rate.

 

Conclusion

The use of non-compliant balloons was associated to a lower rate of events after PCI at long term in patients with bifurcation lesions in coronary arteries.

 

Editorial Comment

Bifurcations are gaining in complexity, as more experienced operators and new stents advance over more challenging lesions.

The new advancement in balloons to improve stent implantation and the new suggested techniques such as proximal optimization (POT) will ensure better results in more and more complex lesions.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

 

Original Title: Impact of non-compliant balloons on long-term clinical outcomes in coronary bifurcation lesion: results from the COBIS (COronary BIfurcation Stent) II registry

Reference: Taek Kyu Park, et al. EuroIntervention2016;12:456-464

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....